Search results
Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat
Zacks via Yahoo Finance· 3 months agoAxsome Therapeutics, Inc. AXSM reported an adjusted loss of 73 cents per share for the fourth...
Axsome (AXSM) Soars 8.1%: Is Further Upside Left in the Stock?
Zacks via Yahoo Finance· 11 months agoAxsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend...
Axsome (AXSM) Stock Up 17% in Six Months: Here's Why
Zacks via Yahoo Finance· 1 year agoAxsome's (AXSM) shares have surged 17.2% in the past six months, owing to the launch of its first product, Auvelity, in October last year. Also, the...
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks via Yahoo Finance· 3 months agoAxsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat...
Axsome (AXSM) Down on Public Offering of Common Stock
Zacks via Yahoo Finance· 11 months agoAxsome AXSM announced that it is floating a secondary issue of 3 million shares of its common stock...
Highly Rated Axsome Surges On Earnings Beat. And Here's Why BioXcel Reversed.
Investor's Business Daily· 1 year agoAxsome Therapeutics and BioXcel Therapeutics issued divergent earnings reports Monday. BTAI stock...
Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss
Zacks via Yahoo Finance· 2 years agoAxsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company...
Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth
Zacks via Yahoo Finance· 1 year agoAxsome Therapeutics AXSM is progressing well with the launch of its first product, Auvelity...
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 2 years agoAxsome (AXSM) delivered earnings and revenue surprises of 6.36% and 1.56%, respectively, for the...
Axsome Wins A 60-Year First In Depression; And Shares Catapult 40%
Investor's Business Daily· 2 years agoThe Food and Drug Administration approved a new depression treatment from Axsome Therapeutics,...